{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "onc-036-checkpoint-inhibitors",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-09T11:10:31.000Z",
    "modified": "2026-01-09T11:10:31.000Z",
    "contributors": [
      "aku-generator"
    ],
    "confidence": 0.85,
    "status": "draft"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/oncology",
    "type": "concept",
    "difficulty": "intermediate",
    "importance": "foundational"
  },
  "content": {
    "title": "Immune Checkpoint Inhibitors",
    "definition": "PD-1/PD-L1 and CTLA-4 inhibitors in cancer treatment",
    "key_points": [
      "Core concept of Immune Checkpoint Inhibitors",
      "Essential understanding of Immune Checkpoint Inhibitors",
      "Clinical/practical relevance of Immune Checkpoint Inhibitors"
    ],
    "clinical_pearls": [
      "Important consideration for Immune Checkpoint Inhibitors"
    ],
    "examples": [
      "Example application of Immune Checkpoint Inhibitors"
    ]
  },
  "relationships": {
    "prerequisites": [],
    "related_concepts": [],
    "applications": []
  }
}